Summary
Gilead Sciences, Inc. reported significant growth in 2014, driven primarily by the successful launches of its Hepatitis C virus (HCV) treatments, Sovaldi and Harvoni. Total revenues surged to $24.9 billion, a substantial increase from $11.2 billion in 2013, with antiviral products accounting for the vast majority of sales. The company also saw strong performance from its HIV portfolio, particularly single-tablet regimens like Stribild and Complera/Eviplera. Despite the strong revenue growth, Gilead experienced a notable increase in operating expenses, including research and development (R&D) and selling, general, and administrative (SG&A) costs, largely due to investments in pipeline progression and expanding commercial infrastructure. The company ended the year with a robust cash position of $11.7 billion, underscoring its financial strength. Gilead also highlighted ongoing efforts to expand access to its medications in developing countries through licensing agreements. Looking ahead, Gilead anticipates continued net product sales growth, supported by expanded access to its HCV treatments and the potential launch of new HIV therapies. However, the company faces ongoing challenges including pricing pressures, competition in the HCV market, potential regulatory hurdles, and significant ongoing litigation related to its key products, particularly sofosbuvir.
Financial Highlights
56 data points| Revenue | $24.89B |
| Cost of Revenue | $3.79B |
| Gross Profit | $21.10B |
| R&D Expenses | $2.85B |
| SG&A Expenses | $2.98B |
| Operating Expenses | $9.63B |
| Operating Income | $15.27B |
| Interest Expense | $412.00M |
| Net Income | $12.10B |
| EPS (Basic) | $7.95 |
| EPS (Diluted) | $7.35 |
| Shares Outstanding (Basic) | 1.52B |
| Shares Outstanding (Diluted) | 1.65B |
Key Highlights
- 1Gilead Sciences achieved a significant revenue milestone in 2014, with total revenues reaching $24.9 billion, more than doubling from $11.2 billion in 2013, primarily driven by the strong performance of its Hepatitis C (HCV) treatments, Sovaldi and Harvoni.
- 2The company's HIV franchise continued its strong performance, with single-tablet regimens like Stribild and Complera/Eviplera showing significant sales increases.
- 3Research and Development (R&D) expenses increased by 35% to $2.9 billion, reflecting continued investment in pipeline development across key therapeutic areas.
- 4Selling, General, and Administrative (SG&A) expenses saw a substantial 76% increase to $3.0 billion, driven by business expansion, particularly in liver diseases and oncology, and increased Branded Prescription Drug (BPD) fees.
- 5Gilead ended 2014 with a strong liquidity position, reporting $11.7 billion in cash, cash equivalents, and marketable securities.
- 6The company is actively managing intellectual property and faces ongoing litigation, notably with Idenix Pharmaceuticals and Merck, concerning its sofosbuvir patents.
- 7Gilead is committed to expanding global access to its medicines, evidenced by non-exclusive licensing agreements with generic manufacturers for HCV and HIV drugs in developing countries.